FLUOXETINE

 

• 6. ANIMAL POISON CONTROL CENTERS
• A. National Animal Poison Control Center, University of Illinois at Urbana-Champaign, 1717 S. Philo Rd. suite 36 Urbana, IL 61802 website www.napcc.aspca.org
• B. NAPCC is an emergency telephone service which provides toxicology information to veterinarians, animal owners, universities, extension personnel and poison center staff for a fee. A veterinary toxicologist is available for consultation.
• C. Two 24 hour phone numbers: (900) 680-0000; (888) 426- 4435 (flat fee of $45, charged to American Express, Discover, VISA, or MasterCard). NAPCC will make follow-up calls as needed in critical cases at no extra charge.
• 11.2.4 DECONTAMINATION
• A. GENERAL TREATMENT
• 1. EMESIS AND LAVAGE - If within 2 hours of exposure, induce emesis with 1 to 2 milliliters/kilogram syrup of ipecac per os. Dogs may vomit more readily with 1 tablet (6 milligrams) apomorphine diluted in 3 to 5 milliliters water and instilled into the conjunctival sac or per os.
• a. Dogs may also be given apomorphine intravenously at 40 micrograms/kilogram, although this route may not be as effective. Do not use an emetic if the animal is hypoxic.
• b. In the absence of a gag reflex or if vomiting cannot be induced, place a cuffed endotracheal tube and begin gastric lavage. Pass large bore stomach tube and instill 5 to 10 milliliters/kilogram water or lavage solution, then aspirate. Repeat 10 times (Kirk, 1986).
• 2. ACTIVATED CHARCOAL - Administer activated charcoal, 2 grams/kilogram per os or via stomach tube. Avoid aspiration by proper restraint, careful technique, and if necessary tracheal intubation.
• 3. CATHARTIC - Administer a dose of a saline cathartic such as magnesium or sodium sulfate (sodium sulfate dose is 1 gram/kilogram). If access to these agents is limited, give 5 to 15 milliliters magnesium oxide (Milk of Magnesia) per os for dilution.
• 11.2.5 TREATMENT
• A. GENERAL TREATMENT
• 1. MAINTAIN VITAL FUNCTIONS - Secure airway, supply oxygen, and begin supportive fluid therapy if necessary.
• 2. SEIZURES -
• a. DIAZEPAM - Dose of diazepam for DOGS & CATS is 0.5 milligram/kilogram intravenous bolus; may repeat dose every ten minutes for four total doses. Give slowly over 1 to 2 minutes.
• b. PHENOBARBITAL may be used as adjunct treatment at 5 to 30 milligrams/kilogram over 5 to 10 minutes intravenously.
• c. REFRACTORY SEIZURES - Consider anaesthesia or heavy sedation. Administer pentobarbital to DOGS & CATS at a dose of 3 to 15 milligrams/kilogram intravenously slowly to effect. The does may need to be repeated in 4 to 8 hours. Be sure to protect the airway.
• 11.4 CONTINUING CARE
• 11.4.1 SUMMARY
• 11.4.1.2 DECONTAMINATION/TREATMENT
• A. GENERAL TREATMENT
• 1. Begin treatment immediately.
• 2. Keep animal warm and do not handle unnecessarily.
• 3. Sample vomitus, blood, urine, and feces for analysis.
• 4. Remove the patient and other animals from the source of contamination.
• 5. Treatment should always be done on the advice and with the consultation of a veterinarian. Additional information regarding treatment of poisoned animals may be obtained from a Board Certified (ABVT) Veterinary Toxicologist (check with nearest veterinary school or veterinary diagnostic laboratory) or the National Animal Poison Control Center.
• 6. ANIMAL POISON CONTROL CENTERS
• A. National Animal Poison Control Center, University of Illinois at Urbana-Champaign, 1717 S. Philo Rd. suite 36 Urbana, IL 61802 website www.napcc.aspca.org
• B. NAPCC is an emergency telephone service which provides toxicology information to veterinarians, animal owners, universities, extension personnel and poison center staff for a fee. A veterinary toxicologist is available for consultation.
• C. Two 24 hour phone numbers: (900) 680-0000; (888) 426- 4435 (flat fee of $45, charged to American Express, Discover, VISA, or MasterCard). NAPCC will make follow-up calls as needed in critical cases at no extra charge.
• 11.4.2 DECONTAMINATION
• 11.4.2.2 GASTRIC DECONTAMINATION
• A. GENERAL TREATMENT
• 1. EMESIS AND LAVAGE - If within 2 hours of exposure, induce emesis with 1 to 2 milliliters/kilogram syrup of ipecac per os. Dogs may vomit more readily with 1 tablet (6 milligrams) apomorphine diluted in 3 to 5 milliliters water and instilled into the conjunctival sac or per os.
• a. Dogs may also be given apomorphine intravenously at 40 micrograms/kilogram, although this route may not be as effective. Do not use an emetic if the animal is hypoxic.
• b. In the absence of a gag reflex or if vomiting cannot be induced, place a cuffed endotracheal tube and begin gastric lavage. Pass large bore stomach tube and instill 5 to 10 milliliters/kilogram water or lavage solution, then aspirate. Repeat 10 times (Kirk, 1986).
• 2. ACTIVATED CHARCOAL - Administer activated charcoal, 2 grams/kilogram per os or via stomach tube. Avoid aspiration by proper restraint, careful technique, and if necessary tracheal intubation.
• 3. CATHARTIC - Administer a dose of a saline cathartic such as magnesium or sodium sulfate (sodium sulfate dose is 1 gram/kilogram). If access to these agents is limited, give 5 to 15 milliliters magnesium oxide (Milk of Magnesia) per os for dilution.
• 12.0 REFERENCES
• 12.2 GENERAL BIBLIOGRAPHY
• 1. AAP: American Academy of Pediatrics, Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics 1994; 93:137-150.
• 2. ACGIH(R): 2001 Threshold Limit Values (TLVs(R)) for Chemical Substances and Physical Agents and Biological Exposure Indices (BEIs(R)). Am Conference Govt Ind Hyg, Inc, Cincinnati, OH, 2001.
• 3. AHA (American Heart Association): Guidelines for cardiopulmonary resuscitation and emergency cardiac care. JAMA 1992; 268:2171-2302.
• 4. AIHA: 1996 Emergency Response Planning Guidelines and Workplace Environmental Exposure Level Guides. American Industrial Hygiene Association, Fairfax, VA, 1996.
• 5. AMA Department of Drugs: Drug Evaluation Subscription. American Medical Association, Chicago, IL, 1991.
• 6. Anon: Fluoxetine and hapatitis. WHO Drug Info 1996; 10:190.
• 7. Anon: Fluoxetine: adverse reaction profile. WHO Drug Info, 1994; 8:213.
• 8. Anon: Pregnancy categories for prescription drugs. FDA Drug Bulletin 1982; 12:24-25.
• 9. Appleby M, Mbewu A & Clarke B: Fluoxetine and ventricular torsade - is there a link (Letter)? Internat J Cardiol 1995; 49:178-180.
• 10. Aronoff GR, Bergstrom RF, Pottratz ST et al: Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 1984; 36:138-144.
• 11. Arya DK: Extrapyramidal symptoms with selective serotonin reuptake inhibitors. Br J Psychiatry 1994; 165:728-733.
• 12. Bakshi R: Fluoxetine and restless legs syndrome. J Neurolog Sci 1996; 142:151-152.
• 13. Balon R: Fluoxetine and sexual dysfunction (letter). JAMA 1995; 273:1489.
• 14. Barak Y, Stein D, Levine J et al: Thyroxine augmentation of fluoxetine treatment for resistant depression in the elderly - an open trial. Hum Psychopharmacol 1996; 11:463-467.
• 15. Barceloux D, McGuigan M, Hartigan-Go K: Position statement: cathartics. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Clin Toxicol 1997; 35:743-752.
• 16. Baumann P & Rochat B: Comparative pharmacokinetics of selective serotonin reuptake inhibitors - a look behind the mirror. Internat Clin Psychopharmacol 1995; 10(Suppl 1):15-21.
• 17. Benazzi F & Mazzoli M: Fluoxetine-induced sexual dysfunction: a dose-dependent effect? Pharmacopsychiat 1994; 27:246.
• 18. Benazzi F: Venlafaxine-fluoxetine interaction. J Clin Psychopharmacol 1999; 19:96-98.
• 19. Bendele RA, Adams ER, Hoffman WP et al: Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res 1992; 52:6931-6935.
• 20. Benfield P, Heel RC & Lewis SP: Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32:481-508.
• 21. Benitz WE & Tatro DS: The Pediatric Drug Handbook, 2nd ed. Year Book Medical Publishers, Chicago, IL, 1988.
• 22. Benitz WE & Tatro DS: The Pediatric Drug Handbook, 3rd ed. Mosby-Year Book Inc, Chicago, IL, 1995.
• 23. Bertschy G, Vandel S & Perault MC: Pharmacokinetic interactions - amitriptyline, fluoxetine and antituberculosis drugs. Therapie 1994; 49:509-512.
• 24. Bharucha KJ & Sethi KD: Complex movement disorders induced by fluoxetine. Mov Disord 1996; 11:324-326.
• 25. Bhatara VS, Magnus RD, Paul KL et al: Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms. Ann Pharmacother 1998; 32:432-436.
• 26. Borys DJ, Setzer SC, Ling LJ et al: Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med 1992; 10:115-120.
• 27. Borys DJ, Setzer SC, Ling LJ et al: The effects of fluoxetine in the overdose patient. Clin Toxicol 1990; 28:331-340.
• 28. Bosch X & Vera M: Aplastic anaemia during treatment with fluoxetine. Lancet 1998; 351:1031.
• 29. Bourgeois JA, Thomas DJ, Johansen T et al: Visual hallucinations associated with fluoxetine and sertraline. J Clin Psychopharmacol 1998; 18:482-483.
• 30. Bowsher DJ, Rowe H, Farid NA et al: Pressor responses to tyramine and norepinephrine after subchronic administration of fluoxetine to man. Life Sci 1988; 42:2569-2575.
• 31. Braitberg G & Curry SC: Seizure after isolated fluoxetine overdose. Ann Emerg Med 1995; 26:234-237.
• 32. Brandes LJ & Cheang M: Brandes and Cheang reply to comments on fluoxetine in carcinogenicity (letter). J Clin Psychopharmacol 1996; 16:337-339.
• 33. Brandes LJ & Cheang M: Letter regarding "response to antidepressants and cancer: cause for concern?" (letter). J Clin Psychopharmacol 1995; 15:84-85.
• 34. Bremner JD: Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry 1984; 45:414-419.
• 35. Briggs GG, Freeman RK & Yaffe SJ: Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 4th ed. Williams & Wilkins, Baltimore, MD, 1994, pp 374-375.
• 36. Brown TM, Skop BP & Mareth TR: Pathophysiology and management of the serotonin syndrome. Ann Pharmacother 1996; 30:527-533.
• 37. Browning WN: Exacerbation of symptoms of multiple scerosis in a patient taking fluoxetine (Letter). Am J Psychiatry 1990; 147:1089.
• 38. Buff DD, Brenner R, Kirtane SS et al: Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991; 52:174-176.
• 39. Burke D & Fanker S: Fluoxetine and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Aust NZ J Psychiatry 1996; 30:295-298.
• 40. Byrd RA & Markham JK: Developmental studies of fluoxetine hydrochloride administered orally to rats and rabbits. Fundam Appl Toxicol 1994; 22:511-518.
• 41. Byrd RA, Brophy GT, Markham JK: Developmental toxicology studies of fluoxetine hydrochloride (I) administered orally to rats and rabbits. Teratology 1989; 39:444.
• 42. Cai Q, Benson MA, Talbot TJ et al: Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 1999; 74:692-694.
• 43. Chamberlain JM, Altieri MA, Futterman C et al; A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Ped Emerg Care, 1997; 13:92-94.
• 44. Chambers CD, Johnson KA, Dick LM et al: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010-1015.
• 45. Chiang WK & Smilkstein MJ: Fluoxetine - monoamine oxidase inhibitor interaction (Abstract). Vet Human Toxicol 1989; 31:369.
• 46. Chouinard G & Steiner W: A case of mania induced by high-dose fluoxetine treatment (Letter). Am J Psychiatry 1986; 143:5:686.
• 47. Chouinard G: A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry 1985; 46:32-37.
• 48. Chyka PA & Seger D: Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. Clin Toxicol 1997; 35:721-736.
• 49. Cohen LS & Rosenbaum JF: Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1997; 336:872-873.
• 50. Cohn JB & Wilcox C: Comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder. J Clin Psychiatry 1985; 46:26-31.
• 51. Coulter DM & Pillans PI: Fluoxetine and extrapyramidal side effects. Am J Psychiatry 1995; 152:122-125.
• 52. Crowson AN & Magro CM: Antidepressant therapy - a possible cause of atypical cutaneous lymphoid hyperplasia. Arch Dermatol 1995; 131:925-929.
• 53. Dekerviler E, Tredaniel J, Revlon G et al: Fluoxetin-induced pulmonary granulomatosis. Eur Resp J 1996; 9:615-617.
• 54. Dent LA & Orrock MW: Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 1997; 17:170-172.
• 55. Dingemanse J, Wallnofer A, Gieschke R et al: Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome." Clin Pharmacol Therap 1998; 63:403-413.
• 56. DOT: 49 CFR 172.101; Table of Hazardous Materials and Special Provisions. Department of Transportation, Washington, DC (includes FRs through) 4/30/96.
• 57. DOT: Appendix B to 49 CFR 172.101 - List of Marine Pollutants. Department of Transportation, Washington, DC (includes FRs through) 4/30/96a.
• 58. Drugdex: Prozac, in: Drugdex Information System, (CD-ROM version), Micromedex, Inc, Englewood, CO (edition expires 8/31/96).
• 59. Dursun SM, Burke JG, Nielsen F et al: SSRI-related toxic serotonin syndrome: improvement of discontinuation of treatment and propranolol. Eur Psychiatr 1997; 12:321-323.
• 60. Ellison JM, Milofsky JE & Ely E: Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990; 51:385-386.
• 61. Elyazigi A, Chaleby K, Gad A et al: Steady-state kinetics of fluoxetine and amitriptyline in patients treated with a combination of these drugs as compared with those treated with amitriptyline alone. J Clin Pharmacol 1995; 35:17-21.
• 62. EPA: 40 CFR 261.2 - 261.24; Characteristics of Hazardous Waste. Environmental Protection Agency, Washington, DC (includes FRs through) 4/30/96.
• 63. EPA: 40 CFR 261.31; Hazardous Wastes from non-specific sources. Environmental Protection Agency, Washington, DC (includes FRs through) 4/30/96a.
• 64. EPA: 40 CFR 261.32; Hazardous Wastes from specific sources. Environmental Protection Agency, Washington, DC (includes FRs through) 4/30/96b.
• 65. EPA: 40 CFR 261.33(e); Discarded commercial chemical products, off-specification species, container residues, and spill residues thereof - Acutely Hazardous Wastes. Environmental Protection Agency, Washington, DC (includes FRs through) 4/30/96c.
• 66. EPA: 40 CFR 261.33(f); Discarded commercial chemical products, off-specification species, container residues, and spill residues thereof - Toxic Wastes. Environmental Protection Agency, Washington, DC (includes FRs through) 4/30/96d.
• 67. EPA: 40 CFR 302.4; Designation, Reportable Quantities, and Notification; List of Hazardous Substances and Reportable Quantities. Environmental Protection Agency, Washington, DC (includes FRs through) 4/30/96e.
• 68. EPA: 40 CFR 355, Appendices A and B; Emergency Planning and Notification; The List of Extremely Hazardous Substances and their Threshold Planning Quantities. Environmental Protection Agency, Washington, DC (includes FRs through) 4/30/96f.
• 69. EPA: 40 CFR 372.65; Specific Toxic Chemical Listings. Environmental Protection Agency, Washington, DC (includes FRs through) 4/30/96g.
• 70. Fabre JF & Crismon L: Efficacy of fluoxetine in outpatients with major depression. Curr Ther Res 1985; 37:115-123.
• 71. Fava M & Rosenbaum JF: Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry 1991; 52:108-111.
• 72. FDA: Poison treatment drug product for over-the-counter human use; tentative final monograph. Fed Register 1985; 50:2244-2262.
• 73. Feighner JP, Boyer WF, Tyler DL et al: Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51:222-225.
• 74. Ferguson JM & Feighner JP: Fluoxetine-induced weight loss in overweight non-depressed humans. Internat J Obesity 1987; 11:163-170.
• 75. Fisch C: Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985; 46:42-44.
• 76. Fisher A, McLean AJ, Purcell P et al: Focal necrotising vasculitis with secondary myositis following fluoxetine therapy. Aust NZ MEd J 1999; 29:375-376.
• 77. Flint AJ, Crosby J & Genik JL: Recurrent hyponatremia associated with fluoxetine and paroxetine (Letter). Am J Psychiatry 1996; 153:134.
• 78. Fontaine R & Chouinard G: Fluoxetine in the long-term maintenance treatment of obsessive compulsive disorder. Psychiatr Ann 1989; 19:88-91.
• 79. Freierabend RH: Benign course in a child with massive fluoxetine overdose. J Fam Practice 1995; 41:289-291.
• 80. Friedenberg FK & Rothstein KD: Hepatitis secondary to fluoxetine treatment (letter). Am J Psychiatry 1996; 153:580.
• 81. Friedman EH: Fluoxetine-induced bradycardia (Letter). J Clin Psychiatry 1991; 52:477.
• 82. Fuller RW, Snoddy HD, Perry KW et al: Importance of duration of drug action in the antagonism of p-chloramphetamine depletion of brain serotonin-comparison of fluoxetine and chlorimipramine. Biochem Pharmacol 1977; 27:193-198.
• 83. Fuller RW: The influence of fluoxetine on aggressive behavior. Neuropsychopharmacol 1996; 14:77-81.
• 84. Gardner SF, Rutherford WF, Munger MA et al: Drug-induced supraventricular tachycardia: a case report of fluoxetine. Ann Emerg Med 1991; 20:194-197.
• 85. Giang DW & McBride MC: Lorazepam versus diazepam for the treatment of status elipticus. Pediatr Neurol 1988; 4:358-361.
• 86. Gillman PK: Ecstasy, serotonin syndrome and the treatment of hyperpyrexia (letter). MJA 1997; 167:109-111.
• 87. Girault C, Richard JC, Chevron V et al: Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine. J Toxicol Clin Toxicol 1997; 35:93-95.
• 88. Goeringer KE, Raymon L, Christian GD et al: Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J Forensic Sci 2000; 45:633-648.
• 89. Goldberg RJ & Huk M: Serotonin syndrome from trazodone and buspirone (letter). Psychosomatics 1992; 33:235-236.
• 90. Goldbloom DS & Kennedy SH: Adverse interaction of fluoxetine and cyproheptadine in two patients with bulimia nervosa. J Clin Psychiatry 1991; 52:261-262.
• 91. Goldstein DA: Personal Communication; April 25, 1997.
• 92. Goldstein DJ, Corbin LA & Sundell KL: Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89:713-718.
• 93. Goldstein DJ, Marvel DE: Psychotropic medications during pregnancy: Risk to the fetus. JAMA 1993; 270:2177.
• 94. Goldstein DJ: Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol 1995; 15:417-420.
• 95. Goldstein DJ: Outcome of fluoxetine-exposed pregnancies. Am J Hum Genet 1990; 47:A136.
• 96. Gommans JH & Edwards RA: Fluoxetine and hyponatraemia. NZ Med J 1990; 14 March:106.
• 97. Gonzalez-Rothi BJ, Zander DS & Ros PR: Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. Chest 1995; 107:1763-1765.
• 98. Goodnough DB, Baker GB & Coutts RT: Simultaneous quantification of fluoxetine, norfluoxetine, and desipramine using gas chromatography with nitrogen-phosphorus detection. J Pharmacol Toxicol Methods 1995; 34:143-147.
• 99. Gorman JM, Liebowitz MR, Fyer AJ et al: An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7:329-332.
• 100. Graham PM: Successful treatment of the toxic serotonin syndrome with chlorpromazine (letter). Med J Australia 1997; 166:166-167.
• 101. Graudins A, Vossler C, & Wang R: Fluoxetine-induced cardiotoxicity with response to bicarbonate therapy. Am J Emerg Med 1997; 15:501-503.
• 102. Gross R, Dannon PN, Lepkifker E et al: Generalized seizures caused by fluoxetine overdose (letter). Am J Emerg Med 1998; 16:328-329.
• 103. Guze BH & Baxter LR Jr: The serotonin syndrome: case responsive to propranolol (letter). J Clin Psychopharmacol 1986; 6:119-120.
• 104. Herman JB, Brotman AW, Pollack MH et al: Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990; 51:25-27.
• 105. Hersh CB, Sokol MS, & Pfeffer CR: Transient psychosis with fluoxetine (Letter). J Am Acad Child Adoles Psychiatry 1991; 30:851.
• 106. Hoes MJAJM: Mirtazapine as treatment for serotonin syndrome. Pharmacopsychiatry 1996; 29:81.
• 107. Hoffman WP & Long GG: Comments on fluoxetine in carcinogenicity (letter). J Clin Psychopharmacol 1996; 16:335-337.
• 108. Hofman M & Liu JK: Conduction abnormality and ventricular tachyarrhythmia associated with fluoxetine overdose (Abstract). Vet Human Toxicol 1994; 36:371
• 109. Hollander JB: Fluoxetine and sexual dysfunction (letter). JAMA 1995; 273:1490.
• 110. Hoover CE: Suicidal ideation not associated with fluoxetine (Letter). Am J Psychiatry 1991; 148:543.
• 111. Hopkins HS: Fluoxetine and sexual dysfunction (letter). JAMA 1995; 273:1489-1490.
• 112. Hoyt JA, Byrd RA, Brophy GT et al: A reproduction study of fluoxetine hydrochloride (I) administered in the diet to rats. Teratology 1989; 39:459.
• 113. HSDB: Hazardous Substance Data Bank. National Library of Medicine, Bethesda, MD, (CD-ROM version), Micromedex, Inc, Englewood, CO (Edition expires 7/31/96).
• 114. Humphries JE, Wheby MS, VandenBerg SR: Fluoxetine and the bleeding time. Arch Pathol Lab Med 1990; 114:727-728.
• 115. Hwang AS & Magraw RM: Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine (Letter). Am J Psychiatry 1989; 146:399.
• 116. Isenberg KE: Excretion of fluoxetine in human breast milk (Letter). J Clin Psychiatry 1990; 51:169.
• 117. Jackson C, Carson W, Markowitz J & Mintzer J: SIADH associated with fluoxetine and sertraline therapy (Letter). Am J Psychiatry 1995; 152:809-810.
• 118. Jackson TW & Hornfeldt CS: Seizure activity following recreational LSD use in patients treated with lithium and fluoxetine (Abstract). Vet Human Toxical 1991; 33:387.
• 119. Jafri AB & Greenberg WM: Fluoxetine side effects (Letter). J Am Acad Child Adoles Psychiatry 1991; 30:852.
• 120. Johnston DE & Wheeler DE: Chronic hepatitis related to use of fluoxetine. Am J Gastroenterol 1997; 92:1225-1226.
• 121. Judge R: Dangers of fluoxetine (letter). Lancet 1997; 349:809.
• 122. Kara H, Aydin S, Agargun MY et al: The efficacy of fluoxetine in the treatment of premature ejaculation - a double-blind placebo controlled study. J Urol 1996; 156:1631-1632.
• 123. Kesavan S & Sobala GM: Serotonin syndrome with fluoxetine plus tramadol. J Royal Soc Med 1999; 92:474-475.
• 124. Kim SW & Pentel PR: Flu-like symptoms associated with fluoxetine overdose: A case report. J Toxicol Clin Toxicol 1989; 27:389-393.
• 125. Kincaid RL, McMullin MM, Crookham SB et al: Report of a fluoxetine fatality. J Anal Toxicol 1990; 14:327-329.
• 126. Kirk RW (Ed): Current Veterinary Therapy IX. Saunders, Philadelphia, PA, 1986.
• 127. Kline MD: Fluoxetine and anorgasmia (Letter). Am J Psychiatry 1989; 6:804-805.
• 128. Kline SS, Mauro LS, Scala-Barnett DM et al: Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharmac 1989; 8:510-514.
• 129. Kulin NA, Pastuszak A, Sage SR et al: Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 1998; 279:609-610.
• 130. Lahat E, Goldman M, Barr J et al: Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomized study. BMJ 2000; 321:83-86.
• 131. Lane R & Baldwin D: Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17:208-221.
• 132. Lee HS, Song DH, Kim CH et al: An open clinical trial of fluoxetine in the treatment of premature ejaculation. J Clin Psychopharmacol 1996; 16:379-382.
• 133. Lemberger L, Bergstrom RF, Wolen RL et al: Fluoxetines, clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46:14-19.
• 134. Lepkifker E, Dannon PN, Iancu I et al: Nightmares related to fluoxetine treatment. Clin Neuropharmacology 1995; 18:90-94.
• 135. LOLI(R): The Regulated Chemicals List of Lists. Compiled by ChemADVISOR, Inc, Pittsburgh, PA (CD-ROM Version). Micromedex, Inc, Englewood, CO (expires 1/31/97).
• 136. Louie AK, Lewis TB, Lannon RA: Use of low-dose fluoxetine in major depression and panic disorder. J Clin Psychiatry 1993; 54:435-438.
• 137. Marchiando RJ, Cook MD & Jue SG: Probable terfenadine-fluoxetine-associated cardiac toxicity (Letter), Ann Pharmacotherapy 1995; 29:937-938.
• 138. Marley E & Wozniak KM: Interactions of a non-selective monoamine oxidase inhibitor, phenelzine, with inhibitors of 5-hydroxytryptamine, dopamine or noradrenaline re-uptake. J Psychiatr Res 1984; 18:173-189.
• 139. Masand P, Gupta S & Dewan M: Suicidal ideation related to fluoxetine treatment (Letter). N Engl J Med 1991; 324:420.
• 140. Mills KC: Serotonin syndrome: a clinical update. Med Toxicol 1997; 13:763-783.
• 141. Mitchell PB: Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Safety 1997; 17:390-406.
• 142. Modell JG: Repeated observations of yawning, clitoral engorgement, and orgasm associated with fluoxetine administration (Letter). J Clin Psychopharmacol 1989; 9:63-65.
• 143. Moore JL & Rodrigues R: Toxicity of fluoxetine in overdose. Am J Psychiatry 1990; 147:1089.
• 144. Nash JF, Bopp RJ, Carmichael RH et al: Determination of fluoxetine and norfluoxetine in plasma by gas chromatography with electron-capture detection. Clin Chem 1982; 28:2100-2109.
• 145. NIOSH: Pocket Guide to Chemical Hazards. National Institute for Occupational Safety and Health, Cincinnati, OH (CD-ROM Version). Micromedex, Inc, Englewood, CO (volume 30, expires 10/31/96).
• 146. Nulman I & Koren G: The safety of fluoxetine during pregnancy and lactation. Teratology 1996; 53:304-308.
• 147. OSHA: 29 CFR 1910.1000; Air contaminants. Department of Labor, Occupational Safety and Health Administration, Washington, DC (includes FRs through) 4/30/96a.
• 148. OSHA: 29 CFR 1910.119; Appendix A, List of Highly Hazardous Chemicals, Toxics and Reactives (Mandatory). Department of Labor, Occupational Safety and Health Administration, Washington, DC (includes FRs through) 4/30/96.
• 149. Pai VB & Kelly MW: Bruising associated with the use of fluoxetine. Ann Pharmacother 1996; 30:786-788.
• 150. Palop V, Sancho a, Morales-Olivas FJ et al: Fluoxetine-associated stomatitis. Ann Pharmacother 1997; 31:1478-1480.
• 151. Pastuszak A, Schick-Boschetto B, Zuber C et al: Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269:2246-2248.
• 152. Pato MT, Murphy DL & DeVane CL: Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation (Letter). J Clin Psychopharmacol 1991; 11:224-225.
• 153. Perse T, Meyers F & Hegyvary C: New perspectives on fluoxetine (Prozac): promixe, problems, and potential dangers. Emerg Med Reports 1991; 12:73-80.
• 154. Phillips S, Heiligenstein J, Birkett M, et al: Fluoxetine vs tricyclic antidepressants: a prospective multicenter study of antidepressant overdoses (Abstract). Vet Human Toxicol 1994; 36:378.
• 155. Pohland RC, Byrd TK, Hamilton M et al: Placental transfer and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol 1989; 98:198-205.
• 156. Pollack PT, Sketris IS, MacKenzie SL et al: Delirium probably induced by clarithromycin in a patient receiving fluoxetine. Ann Pharmacotherapy 1995; 29:486-488.
• 157. Power BM, Pinder M, Hackett LP et al: Fatal serotonin syndrome following a combined overdose of meclobemide, clomipramne and fluoxetine. Anaesth Intens Care 1995; 23:499-502.